Cargando…
Expanding role of lenalidomide in hematologic malignancies
Lenalidomide is an immunomodulatory agent that has been approved by the US Food and Drug Administration for treatment of multiple myeloma, deletion 5q myelodysplastic syndrome, and mantle cell lymphoma. In addition, it has clinical activity in lymphoproliferative disorders and acute myeloid leukemia...
Autores principales: | Ghosh, Nilanjan, Grunwald, Michael R, Fasan, Omotayo, Bhutani, Manisha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427066/ https://www.ncbi.nlm.nih.gov/pubmed/25999761 http://dx.doi.org/10.2147/CMAR.S81310 |
Ejemplares similares
-
Mechanism of action of lenalidomide in hematological malignancies
por: Kotla, Venumadhav, et al.
Publicado: (2009) -
Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies
por: McDaniel, Jessica M., et al.
Publicado: (2012) -
Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies
por: Blumel, Susan, et al.
Publicado: (2014) -
Toward Therapeutic Drug Monitoring of Lenalidomide in Hematological Malignancy? Results of an Observational Study of the Exposure-Safety Relationship
por: Song, Zaiwei, et al.
Publicado: (2022) -
Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies
por: McBride, Ali, et al.
Publicado: (2012)